Physician profile
Rama Anthony
NPI 1689170672
$19,956.80
in general payments reported to CMS, 2019-2025
18 companies · $7,912 in 2025
The $7,912 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $524 · 2022: $5,261 · 2023: $1,974 · 2024: $4,285 · 2025: $7,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,348 · Food and Beverage: $6,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,347.95 |
| Food and Beverage | $6,823.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,390.96 | 2022-2025 | Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $5,844.21 | 2021-2025 | Corevalve Evolut R, Na |
| Abbott Laboratories | $3,292.40 | 2022-2025 | Mitraclip, Navitor, Amplatzer |
| Boston Scientific Corporation | $2,789.45 | 2021-2025 | Watchman Access System, Watchman Flx, Watchman |
| Abbvie INC. | $401.57 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $238.35 | 2023-2024 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $140.00 | 2025 | |
| Amgen INC. | $110.00 | 2024 | Krystexxa |
| Dynavax Technologies Corporation | $108.93 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $105.49 | 2023 | Quviviq |
| Biogen, INC. | $97.98 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $95.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.72 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $70.00 | 2023 | |
| Dexcom, INC. | $66.95 | 2025 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $50.00 | 2025 | Neffy |
| Madrigal Pharmaceuticals | $40.28 | 2025 | Rezdiffra |
| Biosense Webster, INC. | $24.51 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.